OLMA OLEMA PHARMACEUTICALS INC Investments/Divestments 8-K Filing 2024 - Announcement of Development Candidate for KAT6 Program Olema Pharmaceuticals announced the selection of a development candidate for their program targeting KAT6, an epigenetic target in breast cancer and other cancers.Get access to all SEC 8-K filings of the OLEMA PHARMACEUTICALS INC